ProCE Banner Activity

Managing Diarrhea and Interstitial Lung Disease With Newer HER2-Directed Therapies

Clinical Thought

Rita Nanda, MD, discusses tucatinib-associated diarrhea and interstitial lung disease with trastuzumab deruxtecan treatment and offers clinical pearls for their management.

Released: December 02, 2022

Expiration: December 01, 2023

No longer available for credit.



Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Department of Medicine
Director, Breast Oncology
University of Chicago
Chicago, Illinois

Provided by

ProCE Banner


This activity is supported by


Faculty Disclosure

Rita Nanda, MD: researcher: Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate, OncoSec, Pfizer, Seattle Genetics, Taiho; advisor: AstraZeneca, BeyondSpring, Fuji Film, GE, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Sanofi, Seattle Genetics.